Related Experiment Video
Updated: Jul 14, 2026

08:25
Analysis of Coronary Vessels in Cleared Embryonic Hearts
Published on: December 7, 2016
Control of coronary angiogenesis
1Max-Planck-Institute, Department of Experimental Cardiology, Bad Nauheim, Germany.
European Heart Journal
|May 1, 1995
Summary
Canine and porcine hearts develop new blood vessels differently following coronary occlusion. Inflammation and controlled proteolysis are key to forming these coronary collaterals, crucial for heart health.
Area of Science:
- Cardiovascular Biology
- Vascular Biology
- Regenerative Medicine
Background:
- Coronary collateral development is vital for managing ischemic heart disease.
- Understanding species-specific responses to vascular occlusion is crucial for therapeutic development.
- The role of inflammation and extracellular matrix remodeling in neovascularization requires further elucidation.
Purpose of the Study:
- To investigate and compare the development of coronary collaterals in canine and porcine models.
- To elucidate the cellular and molecular mechanisms underlying vascular adaptation to coronary occlusion.
- To highlight the role of inflammation and proteolysis in creating space for new vascular growth.
Main Methods:
- Progressive experimental coronary occlusion in canine and porcine models.
- Microembolism of small vessels in canine and porcine hearts.
- Histological analysis to observe vascular remodeling and cellular infiltration.
- Assessment of inflammatory cell involvement, particularly monocytes/macrophages.
Main Results:
- Canine hearts developed epicardial muscular arteries, while porcine hearts formed intra-myocardial capillaries.
- Vascular adaptation occurred irrespective of the occlusion type (occlusion vs. microembolism).
- Inflammation, involving monocytes/macrophages, was a common feature in both models.
- Controlled proteolysis was essential for remodeling and accommodating new vascular cells.
Conclusions:
- Species-specific differences exist in coronary collateral development pathways.
- Inflammation, mediated by monocytes/macrophages, is a critical initiator of vascular adaptation.
- Controlled proteolysis plays a significant role in facilitating neovascularization within the myocardium.
- These findings provide insights into potential therapeutic targets for enhancing collateral formation in ischemic heart disease.
Related Concept Videos
Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

